Cover Image

Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy

For patients with locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is recommended as standard therapy. So far, no predictive or prognostic molecular factors for patients undergoing multimodal treatment are established. Increased angiogenesis and altered tumour metabolism as adapti...

Full description

Saved in:
Bibliographic Details
Main Authors: Schwaab, Juliana (Author) , Horisberger, Karoline (Author) , Ströbel, Philipp (Author) , Bohn, Beatrice (Author) , Gencer, Deniz (Author) , Kähler, Georg (Author) , Kienle, Peter (Author) , Post, Stefan (Author) , Wenz, Frederik (Author) , Hofmann, Wolf-Karsten (Author) , Hofheinz, Ralf-Dieter (Author) , Erben, Philipp (Author)
Format: Article (Journal)
Language:English
Published: 19 August 2011
In: BMC cancer
Year: 2011, Volume: 11, Pages: 1-9
ISSN:1471-2407
DOI:10.1186/1471-2407-11-363
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1471-2407-11-363
Get full text
Author Notes:Juliana Schwaab, Karoline Horisberger, Philipp Ströbel, Beatrice Bohn, Deniz Gencer, Georg Kähler, Peter Kienle, Stefan Post, Frederik Wenz, Wolf-Karsten Hofmann, Ralf-Dieter Hofheinz and Philipp Erben
Description
Summary:For patients with locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is recommended as standard therapy. So far, no predictive or prognostic molecular factors for patients undergoing multimodal treatment are established. Increased angiogenesis and altered tumour metabolism as adaption to hypoxic conditions in cancers play an important role in tumour progression and metastasis. Enhanced expression of Vascular-endothelial-growth-factor-receptor (VEGF-R) and Transketolase-like-1 (TKTL1) are related to hypoxic conditions in tumours. In search for potential prognostic molecular markers we investigated the expression of VEGFR-1, VEGFR-2 and TKTL1 in patients with LARC treated with neoadjuvant chemoradiotherapy and cetuximab.
Item Description:Gesehen am 28.10.2022
Physical Description:Online Resource
ISSN:1471-2407
DOI:10.1186/1471-2407-11-363

Similar Items